Australian Clinical Labs Ltd (ACL) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.416x

Based on the latest financial reports, Australian Clinical Labs Ltd (ACL) has a cash flow conversion efficiency ratio of 0.416x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$62.87 Million ≈ $44.48 Million USD) by net assets (AU$151.04 Million ≈ $106.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Australian Clinical Labs Ltd balance sheet quality to measure how much of total assets are equity-financed.

Australian Clinical Labs Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how Australian Clinical Labs Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Australian Clinical Labs Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.

Australian Clinical Labs Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Australian Clinical Labs Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shanghai No1 Pharmacy Co Ltd SHG:600833	-0.026x
Propel Funeral Partners Ltd AU:PFP	0.059x
Nh Investment And Securities 1p KO:005945	-0.040x
Onity Group Inc. NYSE:ONIT	-2.526x
D. Boral Acquisition I Corp. Class A Ordinary Shares NASDAQ:DBCA	-0.001x
Aeris Resources Ltd AU:AIS	0.215x
STIF Société anonyme PA:ALSTI	-0.068x
Carindale Property Trust AU:CDP	0.028x

Annual Cash Flow Conversion Efficiency for Australian Clinical Labs Ltd (2016–2025)

The table below shows the annual cash flow conversion efficiency of Australian Clinical Labs Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Australian Clinical Labs Ltd market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$171.98 Million ≈ $121.69 Million	AU$182.80 Million ≈ $129.34 Million	1.063x	0.00%
2024-12-31	AU$171.98 Million ≈ $121.69 Million	AU$182.80 Million ≈ $129.34 Million	1.063x	+18.39%
2024-06-30	AU$177.76 Million ≈ $125.78 Million	AU$159.59 Million ≈ $112.92 Million	0.898x	0.00%
2023-12-31	AU$177.76 Million ≈ $125.78 Million	AU$159.59 Million ≈ $112.92 Million	0.898x	+7.89%
2023-06-30	AU$172.67 Million ≈ $122.18 Million	AU$143.68 Million ≈ $101.66 Million	0.832x	0.00%
2022-12-31	AU$172.67 Million ≈ $122.18 Million	AU$143.68 Million ≈ $101.66 Million	0.832x	-31.88%
2022-06-30	AU$232.56 Million ≈ $164.55 Million	AU$284.09 Million ≈ $201.01 Million	1.222x	0.00%
2021-12-31	AU$232.56 Million ≈ $164.55 Million	AU$284.09 Million ≈ $201.01 Million	1.222x	-34.97%
2021-06-30	AU$81.91 Million ≈ $57.96 Million	AU$153.86 Million ≈ $108.87 Million	1.878x	0.00%
2020-12-31	AU$81.91 Million ≈ $57.96 Million	AU$153.86 Million ≈ $108.87 Million	1.878x	+27.37%
2020-06-30	AU$68.99 Million ≈ $48.81 Million	AU$101.74 Million ≈ $71.98 Million	1.475x	0.00%
2019-12-31	AU$68.99 Million ≈ $48.81 Million	AU$101.74 Million ≈ $71.98 Million	1.475x	+3536.33%
2019-06-30	AU$27.42 Million ≈ $19.40 Million	AU$1.11 Million ≈ $786.81K	0.041x	0.00%
2018-12-31	AU$27.42 Million ≈ $19.40 Million	AU$1.11 Million ≈ $786.81K	0.041x	-95.28%
2018-06-30	AU$5.46 Million ≈ $3.86 Million	AU$4.69 Million ≈ $3.32 Million	0.860x	0.00%
2017-12-31	AU$5.46 Million ≈ $3.86 Million	AU$4.69 Million ≈ $3.32 Million	0.860x	+163.80%
2017-06-30	AU$14.12 Million ≈ $9.99 Million	AU$4.60 Million ≈ $3.26 Million	0.326x	0.00%
2016-12-31	AU$14.12 Million ≈ $9.99 Million	AU$4.60 Million ≈ $3.26 Million	0.326x	--

About Australian Clinical Labs Ltd

AU:ACL Australia Diagnostics & Research

Market Cap

$309.40 Million

AU$437.28 Million AUD

Market Cap Rank

#14491 Global

#391 in Australia

Share Price

AU$2.33

Change (1 day)

+0.00%

52-Week Range

AU$1.84 - AU$2.92

All Time High

AU$5.09